P. Lawrence

发表

Complexity of FGFR signalling in metastatic urothelial cancer

B. Dougherty, A. Rodriguez-Vida, M. Saggese, 2015, Journal of Hematology & Oncology.

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

M. Ranson, J. Schellens, F. André, 2013 .

Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors

M. Ranson, J. Schellens, F. André, 2013 .

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.

M. Socinski, P. Lawrence, P. Mudd, 1998, Anti-cancer drugs.

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK

J. Schellens, U. Banerji, P. Lawrence, 2018, Cancer Chemotherapy and Pharmacology.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

J. Barrett, J. Schellens, P. Elvin, 2017, Clinical Cancer Research.

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

M. Ranson, J. Schellens, K. Tamura, 2013 .

Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.

M. Ranson, J. Schellens, K. Tamura, 2013 .

Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.

J. Barrett, K. Tamura, P. Elvin, 2014 .

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.

J. Schellens, P. Elvin, G. Batist, 2015 .